ACA
ABBV icon

Aspire Capital Advisors’s AbbVie ABBV Stock Holding History

Aspire Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Buy
1,227
+223
+22% +$48K 0.06% 104
2026
Q1 		$218K Sell
1,004
-23
-2% -$5.1K 0.05% 113
2025
Q4 		$235K Buy
+1,027
New +$234K 0.06% 105

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aspire Capital Advisors's ABBV Position: Q2 2026 in Review

Aspire Capital Advisors increased its AbbVie (ABBV) stake by 22% in Q2 2026, buying an estimated $48K and bringing the position to 1,227 shares worth $309K. The position accounts for 0.06% of the portfolio, ranked #104.

Aspire Capital Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Aspire Capital Advisors held 1,227 shares of AbbVie worth $309K as of Q2 2026.
  • Aspire Capital Advisors bought 223 AbbVie shares in Q2 2026, an estimated $48K.
  • AbbVie made up 0.06% of Aspire Capital Advisors's portfolio in Q2 2026, its #104 holding.
  • Aspire Capital Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Aspire Capital Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.